Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.

ABSTRACT:

Background

The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.

Methods

Patients with breast cancer were enrolled in a trial of adjuvant AI therapy. Changes in pain and function during therapy were assessed prospectively. We selected 30 cases with AIMSS and 22 controls without AIMSS, matched for demographics and prior therapy. Serum samples collected at baseline and during treatment were assayed for multiple inflammatory cytokines and lipid mediators using multiplex assays.

Results

Before AI therapy,

SUBMITTER: Henry NL 

PROVIDER: S-EPMC2920022 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature